GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (NAS:NSPR) » Definitions » Piotroski F-Score

InspireMD (InspireMD) Piotroski F-Score : 5 (As of Apr. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is InspireMD Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

InspireMD has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for InspireMD's Piotroski F-Score or its related term are showing as below:

NSPR' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 6
Current: 5

During the past 13 years, the highest Piotroski F-Score of InspireMD was 6. The lowest was 2. And the median was 5.


InspireMD Piotroski F-Score Historical Data

The historical data trend for InspireMD's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD Piotroski F-Score Chart

InspireMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 2.00 6.00 3.00 5.00

InspireMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 5.00 5.00 5.00

Competitive Comparison of InspireMD's Piotroski F-Score

For the Medical Devices subindustry, InspireMD's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where InspireMD's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -4.256 + -5.077 + -5.178 + -5.405 = $-19.92 Mil.
Cash Flow from Operations was -4.831 + -3.325 + -4.043 + -4.177 = $-16.38 Mil.
Revenue was 1.239 + 1.649 + 1.556 + 1.761 = $6.21 Mil.
Gross Profit was 0.373 + 0.491 + 0.438 + 0.505 = $1.81 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(24.653 + 19.921 + 53.638 + 50.02 + 47.643) / 5 = $39.175 Mil.
Total Assets at the begining of this year (Dec22) was $24.65 Mil.
Long-Term Debt & Capital Lease Obligation was $1.04 Mil.
Total Current Assets was $44.16 Mil.
Total Current Liabilities was $6.02 Mil.
Net Income was -4.481 + -4.636 + -4.529 + -4.845 = $-18.49 Mil.

Revenue was 1.183 + 1.531 + 1.431 + 1.026 = $5.17 Mil.
Gross Profit was 0.122 + 0.431 + 0.366 + 0.198 = $1.12 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(39.712 + 35.171 + 32.766 + 28.061 + 24.653) / 5 = $32.0726 Mil.
Total Assets at the begining of last year (Dec21) was $39.71 Mil.
Long-Term Debt & Capital Lease Obligation was $1.20 Mil.
Total Current Assets was $21.33 Mil.
Total Current Liabilities was $5.07 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

InspireMD's current Net Income (TTM) was -19.92. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

InspireMD's current Cash Flow from Operations (TTM) was -16.38. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-19.916/24.653
=-0.807853

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-18.491/39.712
=-0.46562752

InspireMD's return on assets of this year was -0.807853. InspireMD's return on assets of last year was -0.46562752. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

InspireMD's current Net Income (TTM) was -19.92. InspireMD's current Cash Flow from Operations (TTM) was -16.38. ==> -16.38 > -19.92 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=1.038/39.175
=0.02649649

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=1.195/32.0726
=0.03725922

InspireMD's gearing of this year was 0.02649649. InspireMD's gearing of last year was 0.03725922. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=44.159/6.02
=7.33538206

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=21.326/5.07
=4.20631164

InspireMD's current ratio of this year was 7.33538206. InspireMD's current ratio of last year was 4.20631164. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

InspireMD's number of shares in issue this year was 33.627. InspireMD's number of shares in issue last year was 8.036. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.807/6.205
=0.29121676

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.117/5.171
=0.21601238

InspireMD's gross margin of this year was 0.29121676. InspireMD's gross margin of last year was 0.21601238. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=6.205/24.653
=0.25169351

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=5.171/39.712
=0.13021253

InspireMD's asset turnover of this year was 0.25169351. InspireMD's asset turnover of last year was 0.13021253. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

InspireMD has an F-score of 5 indicating the company's financial situation is typical for a stable company.

InspireMD  (NAS:NSPR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


InspireMD Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of InspireMD's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


InspireMD (InspireMD) Business Description

Traded in Other Exchanges
N/A
Address
4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.
Executives
Gary S Roubin director 4300 ROCKMORE RD JACKSON, WYOMING WY 83001
Patrick Verta officer: EVP Clinical/Medical Affairs 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Michael Berman director 735 PALAMAR AVENUE, SUNNYVALE CA 94085
Thomas J Kester director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Paul Stuka director C/O OSIRIS PARTNERS, LLC, ONE LIBERTY SQUARE, 5TH FLOOR, BOSTON MA 02109
Andrea Tommasoli officer: Chief Operating Officer 22, RUE DE LA PLAGE, COLLONGES AU MONT D OR I0 69660
Shane Thomas Gleason officer: VP Global Marketing 18 NORTHAMPTON PL, COTO DE CAZA CA 92679
Kathryn Arnold director 1136 CHESTNUT AVE., WILMETTE IL 60091
Marvin Slosman director, officer: CEO and President 4 MENORAT HAMAOR ST., C/O INSPIREMD, INC., TEL AVIV L3 6744832
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Agustin V Gago officer: EVP, Chief Commercial Officer 256 JERUSALEM AVE, MASSAPEQUA NY 11758
Eric L. Olson officer: VP of Global Sales Operations C/O INSPIREMD, INC., 800 BOYLSTON STREET, 16TH FLOOR, BOSTON MA 02199
Campbell Rogers director C/O INSPIREMD, INC., 800 BOYLSTON STREET, SUITE 16041, BOSTON MA 02199
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Eyal Weinstein director C/O LEOREX LTD., P.O.B. 15067 MATAM, HAIFA L3 31905

InspireMD (InspireMD) Headlines

From GuruFocus

InspireMD Announces Private Placement of Up to $113.6 Million

By sperokesalga sperokesalga 05-15-2023